CoChat

Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention

Open access
Hussman, John P. · 2020 · Frontiers in Pharmacology
Cited by 161

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

With the objective of linking early findings relating to the novel SARS-CoV-2 coronavirus with potentially informative findings from prior research literature, and to promote investigation toward therapeutic response, a coherent cellular and molecular pathway is proposed for COVID-19, consistent with a broad range of observed clinical features and biological markers, and capturing key mediators of pathophysiology. In this proposed pathway, membrane fusion and cytoplasmic entry of SARS-CoV-2 virus via ACE2 and TMPRSS2-expressing respiratory epithelial cells, including pulmonary type-II pneumocytes, provokes an initial immune response featuring inflammatory cytokine production coupled with a weak interferon response, particularly in Type III interferon-dependent epithelial defense. Differentiation of non-classic pathogenic T-cells and pro-inflammatory intermediate monocytes contributes to a skewed inflammatory profile, mediated by membrane-bound immune receptor subtypes (e.g. FcgRIIA) and downstream signaling pathways (e.g. NF-kB p65, p38 MAPK), followed by chemotactic infiltration of monocyte-derived macrophages and neutrophils into lung tissue. Endothelial barrier degradation and capillary leakage contribute to alveolar cell damage. Inflammatory cytokine release, delayed neutrophil apoptosis, and NETosis contribute to pulmonary thrombosis and cytokine storm. These mechanisms are concordant with observed clinical markers in COVID-19, including high expression of inflammatory cytokines on the TNF-alpha/IL-6 axis, elevated neutrophil-to-lymphocyte ratio (NLR), diffuse alveolar damage via cell apoptosis in respiratory epithelia and vascular endothelia, elevated lactate dehydrogenase (LDH) and C-reactive protein (CRP), high production of neutrophil extracellular traps (NETs), depressed platelet count, and thrombosis. Although certain elements are likely to be revised as new findings emerge, the proposed pathway suggests multiple points of investigation for potential therapeutic interventions, including prophylaxis to augment epithelial defense (e.g. AT1 receptor blockade, Type III and Type I interferons, camostat), reduce viral load (e.g. remdesivir + emetine, lopinavir, Abelson kinase inhibition, dopamine D2 antagonists, selective estrogen receptor modulators), and temper pro-inflammatory signaling (e.g. Ang1-7, estradiol, alpha blockers, DHA/EPA, pasireotide), as well as therapeutics targeted toward molecular mediators of the maladaptive COVID-19 immune response (e.g. IL-6, TNF-alpha, IL-17, JAK, CDK9).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.01169

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 161

Metadata

Authors
Hussman, J. P.
Venue
Frontiers in Pharmacology
Published
2020-07-29
Volume
11
Pages
1169-1169
ISSN
1663-9812 (ISSN-L)
OpenAlex
W3046117332
Cited by
161
References
23
FWCI
3.74
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. https://app.cochat.ai/papers/10.3389/fphar.2020.01169
The paper
Hussman, J. P. (2020). Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.01169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.